All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MDS Hub spoke with Guillermo Garcia-Manero, MD Anderson Cancer Center, Houston, US. We asked, How have oral hypomethylating agents changed the management of MDS?
How have oral hypomethylating agents changed the management of MDS?
Garcia-Manero discusses hypomethylating agents in the management of MDS and acute myeloid leukemia (AML). He goes on to describe the challenges associated with hypomethylating agents, such as the route of administration often being intravenous/subcutaneous. Lastly, he talks about oral hypomethylating agents such as azacitidine and decitabine.
Subscribe to get the best content related to MDS delivered to your inbox